Advertisement

Behavioral Health News

Mental health-related jobs are projected to grow three times faster over the next decade than all occupations overall, CNN reported Sept. 7. 

The FDA unveiled a new strategy to tackle the ongoing shortage of ADHD medications that includes streamlining the approval process for new manufacturing facilities and increasing production limits for existing manufacturers, The New York Times reported Sept. 6.

Advertisement

Judges have appointed permanent receivers to oversee the sale of Retreat Behavioral Health's clinics in Florida, Pennsylvania and Connecticut, LancasterOnline reported Sept. 5. 

Spokane, Wash.-based Sacred Heart nurses, technicians, service and maintenance workers are planning to rally in protest of the hospital's plans to permanently close the inpatient child psychiatric unit, KXLY.com reported Sept. 4.

The Drug Enforcement Administration has increased the production limit of Vyvanse, an ADHD drug made by Takeda Pharmaceutical, and its generic versions by 24% to address an ongoing shortage of the medicines in the U.S. 

Individuals without previous mental health concerns taking weight loss medication semaglutide did not have a higher risk of depressive symptoms, suicidal thoughts or behaviors, a study published in JAMA Internal Medicine found. 

Advertisement